|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Baxter Healthcare Corporation |
|---|---|
| Information provided by: | Baxter Healthcare Corporation |
| ClinicalTrials.gov Identifier: | NCT00460486 |
Purpose
The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 0.5 ml in two age strata (stratum A: 16 to 49 years, stratum B: > 50 years), with the first and second vaccinations being administered according to a rapid immunization schedule (12 ± 2 days apart). The third vaccination will be administered approximately 6 months after the first dose.
| Condition | Intervention | Phase |
|---|---|---|
|
Encephalitis, Tick-Borne |
Biological: Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl |
Phase III |
| Study Type: | Interventional |
| Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older |
| Estimated Enrollment: | 330 |
| Study Start Date: | September 2006 |
| Primary Completion Date: | November 2007 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 16 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Male and female subjects will be eligible for participation in this study if they:
Exclusion Criteria:
Subjects will be excluded from participation in this study if they:
Contacts and Locations| Poland | |
| Centrum Badan Farmakologii Klinicznej monipol | |
| Krakow, Poland, 30-969 | |
| "PANTAMED" Sp. z o.o. | |
| Olsztyn, Poland, 10-461 | |
| Niepubliczny ZOZ "Atarax" s.c. | |
| Olsztyn, Poland, 10-117 | |
| Niepubliczny ZOZ "VITA" | |
| Olsztyn, Poland, 10-295 | |
| Principal Investigator: | Baxter BioScience Investigator, MD | Baxter BioScience |
More Information
| Responsible Party: | Baxter Healthcare Corporation ( Katrin Koelling Schlebusch, Clinical Project Manager ) |
| Study ID Numbers: | 690601 |
| Study First Received: | April 13, 2007 |
| Last Updated: | March 27, 2008 |
| ClinicalTrials.gov Identifier: | NCT00460486 History of Changes |
| Health Authority: | Poland: Ministry of Health |
|
Anti-Infective Agents RNA Virus Infections Flaviviridae Infections Flavivirus Infections Nervous System Diseases Formaldehyde Central Nervous System Diseases Central Nervous System Viral Diseases Brain Diseases Pharmacologic Actions |
Encephalitis Tick-Borne Diseases Encephalitis, Tick-Borne Virus Diseases Encephalitis, Viral Disinfectants Central Nervous System Infections Therapeutic Uses Arbovirus Infections Encephalitis, Arbovirus |